November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Myeloma Paper of the Day, November 14th, suggested by Robert Orlowski
Nov 14, 2024, 14:05

Myeloma Paper of the Day, November 14th, suggested by Robert Orlowski

Robert Orlowski shared a post on X:

“Myeloma Paper of the Day: Allogeneic transplant for therapy-related myeloid neoplasms after myeloma treatment shows long-term survival in <30%, is limited by high t-MN relapse, and older patients with poor risk cytogenetics derive little benefit.”

Allogeneic hematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for multiple myeloma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

Authors: Kavita Raj, Diderik-Jan Eikema, Sarah Lawless, Linda Koster, Desiree Kunadt, Nicolaus Kröger, Uwe Platzbecker, Matthias Stelljes, Wolfgang Bethge, Tobias Holderried, Renato Fanin, Robert Zeiser, Jürgen Kuball, Véronique Leblond, Emma Nicholson, Jakob Passweg, Victoria Potter, Jacques-Olivier Bay, Ali Bazarbachi, Lucía López Corral, Carmelo Gurnari, Christof Scheid, Joanna Drozd-Sokolowska, Treen Curly Morris, Patrick Hayden, Ibrahim Yakoub-Agha, Marie Robin and Donal P. McLornan.

Myeloma Paper of the Day, November 14th, suggested by Robert Orlowski

More posts featuring Robert Orlowski.

Robert Orlowski, M.D., Ph.D., holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine. Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.

Dr. Orlowski’s expertise lies in both clinical practice and scientific research, with a particular focus on translating laboratory discoveries into effective treatments for patients. He investigates drug resistance mechanisms in myeloma and seeks to identify predictive biomarkers for treatment response. Notably, his past contributions include leadership roles in developing proteasome inhibitors like bortezomib and carfilzomib, as well as monoclonal antibodies such as daratumumab and elotuzumab.